Progesterone Dermatitis (Progestogen Hypersensitivity) Presenting as a Polymorphic Drug Eruption After Oral Norethisterone: A Case Report

Progestogen hypersensitivity (PH) describes hypersensitivity reactions to endogenous progesterone, classically termed autoimmune progesterone dermatitis, or to exogenous progestogens. Non-cyclical presentations can be difficult to distinguish from other dermatoses. We describe a case of a 46-year-old woman who developed a widespread pruritic rash 52 days after starting oral norethisterone for heavy menstrual bleeding. The rash began on her arms and progressed to involve the trunk and legs, with papules, pustules, confluent erythema, and crusting. Purpuric, targetoid lesions later developed on her lower legs, followed by pompholyx-like vesicles on her palms and a periorbital eczematous rash. Her eosinophil count was 1.2×109/L (normal range: 0.02-0.50x109/L) and C-reactive protein 16 mg/L (normal range: <5 mg/L). She was afebrile, with no mucosal involvement and no evidence of hepatic or renal dysfunction at presentation. Herpes simplex and varicella-zoster PCR were negative. Skin biopsy showed acanthosis, parakeratosis, and spongiosis, with a dermal infiltrate of lymphocytes and eosinophils. The clinical differentials included a drug eruption, pustular folliculitis, atypical pityriasis rubra pilaris, and erythema multiforme. Norethisterone was stopped, and she was treated with potent topical corticosteroids and a six-week tapering course of oral prednisolone, starting at 30 mg daily. Her skin was largely clear about nine weeks after norethisterone was stopped, with no relapse to date. Discussion at the clinicopathological meeting concluded that this was a delayed-type hypersensitivity reaction to norethisterone, consistent with exogenous PH. She declined a progesterone challenge and was advised to avoid progestogen-containing hormone therapy. This case describes a polymorphic, non-cyclical presentation of PH caused by an oral synthetic progestogen. It may complicate future management of menopausal symptoms, as women with an intact uterus usually require a progestogen alongside estrogen therapy to protect the endometrium.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-16
DOI
https://doi.org/10.7759/cureus.119731
Primary Topic
Drug-Induced Adverse Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Progesterone Dermatitis (Progestogen Hypersensitivity) Presenting as a Polymorphic Drug Eruption After Oral Norethisterone: A Case Report

M Vatve, Ishika Singh
Cureus
Drug-Induced Adverse Reactions
article

Progesterone Dermatitis (Progestogen Hypersensitivity) Presenting as a Polymorphic Drug Eruption After Oral Norethisterone: A Case Report

M Vatve, Ishika Singh
article en

Abstract

Progestogen hypersensitivity (PH) describes hypersensitivity reactions to endogenous progesterone, classically termed autoimmune progesterone dermatitis, or to exogenous progestogens. Non-cyclical presentations can be difficult to distinguish from other dermatoses. We describe a case of a 46-year-old woman who developed a widespread pruritic rash 52 days after starting oral norethisterone for heavy menstrual bleeding. The rash began on her arms and progressed to involve the trunk and legs, with papules, pustules, confluent erythema, and crusting. Purpuric, targetoid lesions later developed on her lower legs, followed by pompholyx-like vesicles on her palms and a periorbital eczematous rash. Her eosinophil count was 1.2×109/L (normal range: 0.02-0.50x109/L) and C-reactive protein 16 mg/L (normal range: <5 mg/L). She was afebrile, with no mucosal involvement and no evidence of hepatic or renal dysfunction at presentation. Herpes simplex and varicella-zoster PCR were negative. Skin biopsy showed acanthosis, parakeratosis, and spongiosis, with a dermal infiltrate of lymphocytes and eosinophils. The clinical differentials included a drug eruption, pustular folliculitis, atypical pityriasis rubra pilaris, and erythema multiforme. Norethisterone was stopped, and she was treated with potent topical corticosteroids and a six-week tapering course of oral prednisolone, starting at 30 mg daily. Her skin was largely clear about nine weeks after norethisterone was stopped, with no relapse to date. Discussion at the clinicopathological meeting concluded that this was a delayed-type hypersensitivity reaction to norethisterone, consistent with exogenous PH. She declined a progesterone challenge and was advised to avoid progestogen-containing hormone therapy. This case describes a polymorphic, non-cyclical presentation of PH caused by an oral synthetic progestogen. It may complicate future management of menopausal symptoms, as women with an intact uterus usually require a progestogen alongside estrogen therapy to protect the endometrium.

CureusVol. 18(11)
Sandwell & West Birmingham Hospitals NHS Trust (GB), County Durham and Darlington NHS Foundation Trust (GB)
Good health and well-being
Drug-Induced Adverse Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon